Water vapor or laser: which prostate treatment saves your sex life?
NCT ID NCT07648875
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two procedures for enlarged prostate: water vapor therapy (Rezum) and a special laser technique that aims to preserve ejaculation. 120 sexually active men aged 50+ with moderate-to-severe symptoms will choose their treatment after counseling. The main goal is to see which approach better maintains ejaculatory function over 12 months, while also tracking urinary relief and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Water vapor thermal therapy (Rezum) and ejaculation-preserving holmium laser enucleation of the prostate (EP-HoLEP)
- What this could lead to
- If this trial succeeds, it could show which procedure better preserves ejaculatory function while treating enlarged prostate symptoms, helping men choose the right option.
- What could go wrong
- This is a small, non-randomized study with 120 participants, so results may not apply to all men. Both procedures carry risks like infection, bleeding, or urinary problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male patients aged 50 years or older. * Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms. * International Prostate Symptom Score (IPSS) of 13 or higher. * Prostate volume 30 to 80 mL measured by transrectal ultrasound. * Maximum urinary flow rate (Qmax) of 15 mL/s or less with voided volume of at least 150 mL. * Post-void residual urine volume of 250 mL or less. * Failure, intolerance, or unwillingness to continue medical therapy for benign prostatic hyperplasia. * Sexually active within the previous 3 months. * Preserved antegrade ejaculation at baseline. * Patient wishes to preserve ejaculation. * Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF). * Written informed consent. Exclusion Criteria: * Suspected or confirmed prostate cancer. * Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice. * Previous prostate surgery. * Previous urethral surgery likely to affect instrumentation or study outcomes. * Urethral stricture disease. * Neurogenic bladder dysfunction. * Active urinary tract infection until adequately treated. * Bladder stones requiring concomitant surgery. * Prostate volume less than 30 mL or more than 80 mL. * Baseline anejaculation or severe ejaculatory dysfunction. * No sexual activity during the previous 3 months. * Chronic indwelling urethral or suprapubic catheter. * Suspected detrusor underactivity requiring urodynamic clarification. * Post-void residual urine volume more than 250 mL. * Uncontrolled coagulopathy. * Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively. * Unfitness for anesthesia or intervention. * Inability or unwillingness to comply with follow-up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign prostatic hyperplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Urology- Beni-Suef University Hospitals
RECRUITINGBanī Suwayf, Beni Suweif Governorate, 02456, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Laser prostate surgery that spares ejaculation put to a Five-Year test
- Virtual basket laser mode put to the test for faster prostate surgery
- Steam therapy vs. surgery: can a less invasive fix help men with blocked urine flow?
- Listening to patients: a new way to guide prostate treatment?
- A surgical twist that could save ejaculation during prostate surgery
- Water jet surgery: a new wave for prostate relief?